|
SEED Grant |
Timothy O'Connor |
Sources of Genetic Instability in Human Embryonic Stem Cells. |
$327,311 |
|
Disease Team Planning |
Michael Barish |
Genetically-modified neural stem cells for treatment of high-grade glioma |
$55,000 |
|
Conference |
Fouad Kandeel |
2013 Rachmiel Diabetes and Obesity Levine Symposium - Advances in Diabetes Research |
$27,750 |
|
Conference - The 2017 Alpha Stem Cell Clinic Annual Symposium |
John Zaia |
2nd Annual Symposium of the CIRM Alpha Stem Cell Clinics Network
"Alpha Clinics - Making the Future a Reality for Stem Cell-Based Therapies" |
$79,287 |
|
Late Stage Preclinical Projects |
Xiuli Wang |
CMV-specific T cells expressing anti-HIV CAR and CMV vaccine boost as immunotherapy for HIV/AIDS |
$3,812,797 |
|
SPARK |
David Ann |
Train, Educate, and Accelerate Mastery of Stem cell research (TEAMS) program |
$508,750 |
|
Tools and Technologies I |
Larry Couture |
Development of Suspension Adaptation, Scale-up cGMP Banking and Cell Characterization Technologies for hESC Lines |
$882,929 |
|
Strategic Partnership III Track A |
John Zaia |
A Phase I, Open-Label Study To Assess The Safety, Feasibility and Engraftment of Zinc Finger Nucleases (ZFN) CCR5 Modified Autologous CD34+ Hematopoietic Stem/Progenitor Cells (SB-728MR-HSPC) with Escalating Doses of Busulfan In HIV-1 (R5) Infected Sub... |
$5,583,438 |
|
Conference |
Fouad Kandeel |
2011 Rachmiel Levine Diabetes and Obesity Symposium: Advances in Diabetes Research |
$15,000 |
|
Quest - Discovery Stage Research Projects |
Markus Müschen |
Lgr5-mediated self-renewal in B cell selection and leukemia-initiation |
$2,186,520 |
|
Clinical Trial Stage Projects |
Saul Priceman |
A Phase I Study of Chimeric Antigen Receptor Engineered Stem/Memory T Cells for the Treatment of HER2-Positive Brain Metastases |
$9,015,149 |
|
Clinical Trial Stage Projects |
Jana Portnow |
A Phase I Study of Multiple doses of NSC-Based Oncolytic Virotherapy Administered Intracerebrally to Patients with Recurrent High-Grade Gliomas |
$11,999,984 |
|
New Faculty I |
Tiziano Barberi |
Skeletal muscle development from hESC and its in vivo applications in animal models of muscular dystrophy |
$131,840 |
|
Alpha Stem Cell Clinics |
John Zaia |
The Innovation-Alpha Clinic for Cellular Therapies (I-ACT) – A Program for the Development and Delivery of Innovative Cell-based Treatments and Cures for Life-threatening Diseases. |
$8,456,000 |
|
Conference |
Fouad Kandeel |
2012 Rachmiel Levine Diabetes and Obesity Symposium: Advances in Diabetes Research |
$15,000 |
|
Quest - Discovery Stage Research Projects |
Yuan Chen |
A Novel Approach to Eradicate Cancer Stem Cells |
$1,539,935 |
|
Therapeutic Translational Research Projects |
Karen Aboody |
Neural Stem cell-mediated oncolytic immunotherapy for ovarian cancer |
$2,873,262 |
|
Alpha Stem Cell Clinics Network Expansion |
Leo Wang |
The City of Hope Alpha Clinic: A roadmap for equitable and inclusive access to regenerative medicine therapies for all Californians |
$8,000,000 |
|
Basic Biology III |
Jiing-Kuan Yee |
Use of human iPS cells to study spinal muscular atrophy |
$1,268,868 |
|
Tools and Technologies III |
Joseph Gold |
Development of a scalable, practical, and transferable GMP-compliant suspension culture-based differentiation process for cardiomyocyte production from human embryonic stem cells. |
$891,518 |
|
Conference |
Richard Jove |
New Approaches in Cell Based Therapies |
$20,000 |
|
Clinical Trial Stage Projects |
Christine Brown |
Phase I Study of Chimeric Antigen Receptor Engineered Central Memory T cells for the Treatment of Malignant Glioma |
$12,753,854 |
|
Clinical Trial Stage Projects |
John Zaia |
Evaluation and Characterization of SARS-CoV-2 Antibody in Convalescent Volunteer Plasma Donors for Potential Therapeutic Use |
$999,999 |
|
Therapeutic Translational Research Projects |
Jianhua Yu |
Specific Targeting Hypoxia Metastatic Breast Tumor with Allogeneic Off-the-Shelf Anti-EGFR CAR NK Cells Expressing an ODD domain of HIF-1α |
$6,036,002 |
|
Early Translational II |
Yanhong Shi |
Developing a therapeutic candidate for Canavan disease using induced pluripotent stem cell |
$1,835,983 |
|
Research Training II |
Michael Barish |
City of Hope Research Training Program in Stem Cell Biology |
$2,197,782 |
|
SPARK |
Paul Salvaterra |
SPARK Award Program in Stem Cell Biology for California High School Students |
$241,080 |
|
Conference |
Richard Jove |
Innovation and Translational Stem Cell Therapy for Diabetes and Neurological Diseases: Paving the way for real life solutions |
$14,878 |
|
Quest - Discovery Stage Research Projects |
Saswati Chatterjee |
Genome Editing of Sinusoidal Endothelial Stem Cells for Permanent Correction of Hemophilia A |
$2,182,193 |
|
Discovery Research Projects |
Jianhua Yu |
Persistent Off-the-Shelf meACE2-CAR-IL-15 NK Cells Derived from CD34(+) Cord Blood Stem Cells to Prevent and Treat COVID-19 |
$150,000 |
|
Quest - Discovery Stage Research Projects |
Jianhua Yu |
Reprogramming Somatic Cells into iPSCs Engineered with an Anti-PSCA CAR to Develop Allogeneic Off-the-Shelf Cell Therapy to Treat Pancreatic Cancer |
$2,263,500 |
|
Early Translational II |
David DiGiusto |
Development of RNA-based approaches to stem cell gene therapy for HIV |
$3,097,160 |
|
Early Translational III |
Stephen Forman |
Targeting glioma cancer stem cells with receptor-engineered self-renewing memory T cells |
$5,215,447 |
|
Therapeutic Translational Research Projects |
Yanhong Shi |
Process development for establishing an iPSC-based therapeutic candidate for Canavan disease |
$7,377,384 |
|
Conference |
Richard Jove |
Innovative Partnerships: Bringing Stem Cell Discoveries to the Clinic |
$14,994 |
|
Clinical Trial Stage Projects |
De-Fu Zeng |
Treatment of sickle cell disease by induction of mixed chimerism and immune tolerance using CD4+ T-depleted haploidentical blood stem cell transplant |
$4,352,180 |
|
Quest - Discovery Stage Research Projects |
Yanhong Shi |
Combating COVID-19 using human PSC-derived NK cells |
$249,998 |
|
Therapeutic Translational Research Projects |
Michael Caligiuri |
Targeting multiple myeloma with BCMA-CAR NK cells expressing a GPRC5D-NKG2D bispecific antibody |
$6,036,001 |
|
Disease Team Research I |
Karen Aboody |
Stem Cell-mediated Therapy for High-grade Glioma: Toward Phase I-II Clinical Trials |
$17,890,623 |
|
Basic Biology IV |
Yanhong Shi |
Modeling Alexander disease using patient-specific induced pluripotent stem cells |
$1,366,656 |
|
Conference II |
Fouad Kandeel |
2016 Rachmiel Levine-Arthur Riggs Diabetes Research Symposium |
$10,000 |
|
Conference |
Fouad Kandeel |
15th Annual Rachmiel Levine Diabetes and Obesity Symposium |
$20,000 |
|
Late Stage Preclinical Projects |
John Zaia |
Ex Vivo Gene Engineering of Blood Stem Cells for Enhanced Chemotherapy Efficacy in Glioblastoma Patients |
$3,684,259 |
|
Clinical Trial Stage Projects |
Leo Wang |
Phase I Study of IL13Rα2-Targeting CAR T Cells After Lymphodepletion for Children with Refractory or Recurrent Malignant Brain Tumors |
$8,401,309 |
|
Disease Team Research I |
John Zaia |
ZINC FINGER NUCLEASE-BASED STEM CELL THERAPY FOR AIDS |
$14,536,969 |
|
Creativity Awards |
Paul Salvaterra |
Creativity Award Program in Stem Cell Biology for California High School Students |
$260,825 |
|
Conference |
Fouad Kandeel |
2009 Rachmiel Levine Diabetes and Obesity Symposium: Advances in Diabetes Biology, Immunology and Cell Therapy |
$15,000 |
|
Conference - Manage The SPARK Annual Meeting |
Paul Salvaterra |
Manage the 2017 SPARK Annual Meeting |
$22,555 |
|
Quest - Discovery Stage Research Projects |
Saul Priceman |
Chimeric Antigen Receptor-Engineered Stem/Memory T Cells for the Treatment of Recurrent Ovarian Cancer |
$1,351,174 |
|
Research Training Grant |
Michael Barish |
Research Training Program in Stem Cell Biology and Regenerative Medicine |
$4,860,989 |
